GeneDx will perform WGS sequencing and analysis on samples from 350 individuals. Credit: PublicDomainPictures from Pixabay.

PacBio and GeneDx have entered a research collaboration with the University of Washington for studying HiFi long-read whole genome sequencing (WGS) capabilities to enhance diagnostic rates in paediatric patients with genetic conditions.

GeneDx will carry out WGS sequencing and analyse samples from 350 individuals, including 120 from the SeqFirst WGS study at Seattle Children’s Hospital, along with available biological parent duos and trios.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Scientists will utilise both short and long-read WGS to examine whether previously undiscovered genetic variants linked to specific genetic conditions can be revealed.

Leveraging the PacBio Revio sequencing system, GeneDx will conduct all long-read WGS sequencing and analysis in the study.

The study’s goal is to determine whether the increased accuracy, read-length and methylation insights provided by the Revio system will allow collaborators to explore and potentially amplify diagnostic yield.

See Also:

The newly identified variants and their frequencies within the sequencing data will be shared with the Consortium of Long Read Sequencing database to enhance variant prevalence and classification understanding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PacBio president and CEO Christian Henry said: “We are honoured to launch this new study with GeneDx and the University of Washington with the aim to bring together the power of the latest developments and capabilities applied to these critical populations.”

GeneDx-sponsored SeqFirst, partly funded by the Brotman Baty Institute, functions as a hub for genomic research and precision medicine, and as a partnership among UW Medicine, Seattle Children’s Hospital and Fred Hutchinson Cancer Center.

Earlier, PacBio collaborated with Google for implementing the deep learning technique known as DeepConsensus into the Revio system to enhance the performance of long-read WGS by leveraging the power of DeepVariant.